Drugmaker Merck has asked U.S. regulators to authorize its promising pill protecting against COVID-19, setting the stage for a decision within weeks.
Researchers are developing vaccines that could be taken as a capsule, a dissolvable tablet or a nasal spray. But the barriers to success are high.among patients with early symptoms of COVID-19. The results were so strong that independent medical experts monitoring the trial recommended stopping it early.
Since the beginning of the pandemic, health experts have stressed the need for a convenient pill. The goal is for something similar to Tamiflu, the 20-year-old flu medication that shortens illness by a day or two and blunts the severity of symptoms such as fever, cough and stuffy nose.Black and Latino residents who aren’t vaccinated have L.A. County’s highest rate of COVID-19. Unvaccinated white people have the highest death rates.
Merck’s Kartsonis said in an interview that the $700 figure does not represent the final price for the medication.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Covid-19: Three more Covid-related deaths and 1,115 new casesThe total number of coronavirus-linked deaths in NI since the start of the pandemic is 2,588.
Lire la suite »
Covid-19: NHS Covid passes, and lockdown lifted in SydneyFive things you need to know about the coronavirus pandemic this Monday morning.
Lire la suite »
Merck seeks FDA emergency use authorization for antiviral Covid-19 treatment molnupiravirMerck said it is seeking FDA emergency use authorization for its experimental antiviral Covid-19 treatment, molnupiravir.
Lire la suite »
Brazil passes grim milestone of 600,000 Covid-19 deaths, second only to USBrazil on Friday surpassed the grim milestone of 600,000 Covid-19 deaths, the second-highest number of fatalities in the world after the United States, according to John Hopkins University data.
Lire la suite »